GlassScriptPhysician profile
Melissa A Morgan
NPI 1821071903
$28,330.04
in general payments reported to CMS, 2019-2025
32 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,227 · 2020: $9,419 · 2021: $9,393 · 2022: $4,904 · 2023: $20.52 · 2024: $22.05 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23,571.54 | 2019-2022 | |
| Novo Nordisk INC | $632.97 | 2019-2021 | |
| Insulet Corporation | $544.05 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $370.45 | 2019-2020 | |
| Amgen INC. | $326.37 | 2019-2021 | |
| Mannkind Corporation | $323.53 | 2019-2020 | |
| Lilly USA, LLC | $278.92 | 2019-2020 | |
| Medtronic Minimed, INC. | $274.03 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.44 | 2019-2021 | |
| Aroa Biosurgery Incorporated | $200.36 | 2025 | |
| Abbott Laboratories | $182.87 | 2019-2021 | |
| Zealand Pharma US, INC. | $177.94 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $163.90 | 2019-2020 | |
| Valeritas, INC. | $161.19 | 2019 | |
| Dexcom, INC. | $117.73 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $100.25 | 2019-2020 | |
| Corcept Therapeutics | $89.30 | 2019 | |
| Abbvie INC. | $87.45 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $81.53 | 2020 | |
| Sanofi Pasteur INC. | $75.83 | 2021-2024 | |
| Shire North American Group INC | $75.20 | 2019 | |
| Ibsa Pharma INC. | $45.81 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $43.20 | 2019 | |
| Horizon Therapeutics Plc | $35.53 | 2019 | |
| Alexion Pharmaceuticals, INC. | $31.15 | 2020 | |
| Antares Pharma, INC. | $17.63 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.83 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $15.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.58 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.64 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.13 | 2019 | |
| Vivus LLC | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.